Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

RADNOR, PA – June 22, 2026 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced the launch of Bio Venture Catalyst, a new integrated strategic offering designed to help emerging biotech companies transform scientific innovation into investor-ready development opportunities.

Bio Venture Catalyst combines scientific, regulatory, commercial and investor-focused expertise to help early-stage biotech companies evaluate opportunities, prioritize development decisions, reduce risk, and build credible pathways to clinical and commercial value creation.

In today’s increasingly challenging biotech funding environment, companies are under growing pressure to demonstrate not only innovative science, but also a sound value proposition based on differentiated development strategy, capital efficiency, and a clear path to regulatory and commercial success. Bio Venture Catalyst is designed to address these challenges through integrated support spanning asset prioritization, MIDD (model-informed drug-development) focused regulatory and development strategy, commercial assessment and investor positioning.

“Strong science is the starting point, not the finish line. Bio Venture Catalyst gives emerging biotech companies the model-informed development strategies, regulatory clarity, and investor confidence they need to move faster and smarter, with less risk at every stage”, said Fran Brown, SVP, Global Head of Drug Development Science at Certara.

Bio Venture Catalyst provides tailored support packages aligned to different stages of company growth, from pre-seed and seed-stage opportunity assessments through Series B+ development and commercialization planning. It is designed to help biotech companies strengthen investor readiness through:

• An integrated concept-to-clinic continuum that combines early development strategy, due diligence, and investor positioning to align scientific and commercial decision-making.
• Investor-ready positioning helps companies articulate differentiated value, development readiness and commercial potential to investors, strategic partners, and other stakeholders.
• Data-driven de-risking powered by Certara’s scientific and regulatory expertise and leadership in model-informed drug development to reduce uncertainty and improve decision quality.
• Proven credibility with investors is backed by deep experience supporting biotech fundraising, strategic partnerships, due diligence, and value creation initiatives.
• Cross-functional expertise spanning translational science, clinical development, regulatory strategy, market opportunity assessment, and commercialization planning.

Bio Venture Catalyst builds on Certara’s decades of experience supporting emerging biotech companies across development strategy, regulatory planning, and commercialization initiatives designed to accelerate drug development and improve decision quality. Since 2014, more than 90% of FDA novel drug approvals have come from Certara clients.

As funding environments continue to evolve, Bio Venture Catalyst is designed to help emerging biotech companies make informed, strategic, and investor-aligned decisions from discovery through early clinical development.

More information about Bio Venture Catalyst is available at www.certara.com/services/bio-venture-catalyst.

To learn more about strategies for building IND-ready and investor-ready development programs, register for Certara’s upcoming webinar, Building IND-Ready and Investor-Ready Development Programs at: https://www.certara.com/webinar/building-ind-ready-and-investor-ready-development-programs/.